Clinical trial
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
NCT00849017
Study timeline
Study start (unknown)2009-01-01Date precision: month
Registry last updated2017-01-09
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Diabetes Mellitus, Type 2unresolved
Interventions
Sponsors & collaborators
GlaxoSmithKlinelead sponsor
Mapped research locations
HoustonTexas, United States8San AntonioTexas, United States6DallasTexas, United States4AtlantaGeorgia, United States4San DiegoCalifornia, United States4Los AngelesCalifornia, United States3OmahaNebraska, United States3Salt Lake CityUtah, United States3Las VegasNevada, United States3BirminghamAlabama, United States2GreenvilleSouth Carolina, United States2HonoluluHawaii, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00849017 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.